Key Points
- Director sale: Castle Biosciences Director G. Bradley Cole sold 7,403 shares at an average price of $28.47 for $210,763, reducing his holding by 27.71% to 19,309 shares, per an SEC filing.
- Quarterly results: The company reported a narrower-than-expected loss of $0.08 per share (vs. -$0.23 estimate) and revenue of $81.88M, but remains unprofitable; analysts’ consensus target is $47.57 with mostly Buy ratings.
- Stock profile: Shares opened at $27.02 (down ~0.4%), market cap about $803M, 52-week range $14.59–$44.28, negative P/E, and institutional ownership around 92.6%.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) CFO Frank Stokes sold 6,001 shares of the business's stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $27.98, for a total transaction of $167,907.98. Following the transaction, the chief financial officer owned 60,085 shares in the company, valued at $1,681,178.30. The trade was a 9.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Frank Stokes also recently made the following trade(s):
- On Tuesday, March 3rd, Frank Stokes sold 7,000 shares of Castle Biosciences stock. The shares were sold at an average price of $27.44, for a total transaction of $192,080.00.
Castle Biosciences Stock Down 0.4%
CSTL stock opened at $27.02 on Tuesday. The company has a current ratio of 5.26, a quick ratio of 5.11 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average of $35.68 and a two-hundred day moving average of $31.62. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The company has a market cap of $803.30 million, a price-to-earnings ratio of -31.79 and a beta of 1.09.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.15. The business had revenue of $81.88 million for the quarter, compared to analysts' expectations of $81.19 million. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%. As a group, analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Castle Biosciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd raised its position in Castle Biosciences by 188.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,099 shares of the company's stock valued at $82,000 after purchasing an additional 1,371 shares during the period. Invesco Ltd. grew its holdings in shares of Castle Biosciences by 142.6% during the 4th quarter. Invesco Ltd. now owns 135,461 shares of the company's stock worth $5,269,000 after purchasing an additional 79,621 shares during the period. Mackenzie Financial Corp increased its position in shares of Castle Biosciences by 54.2% during the 4th quarter. Mackenzie Financial Corp now owns 37,317 shares of the company's stock worth $1,464,000 after purchasing an additional 13,113 shares during the last quarter. Empowered Funds LLC increased its position in shares of Castle Biosciences by 24.2% during the 4th quarter. Empowered Funds LLC now owns 121,920 shares of the company's stock worth $4,743,000 after purchasing an additional 23,740 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Castle Biosciences in the 4th quarter valued at about $861,000. Institutional investors and hedge funds own 92.60% of the company's stock.
Analyst Ratings Changes
Several analysts have issued reports on CSTL shares. Lake Street Capital upped their target price on Castle Biosciences from $35.00 to $52.00 and gave the company a "buy" rating in a report on Monday, January 12th. Zacks Research lowered Castle Biosciences from a "strong-buy" rating to a "hold" rating in a report on Monday, March 2nd. Weiss Ratings reissued a "sell (d)" rating on shares of Castle Biosciences in a research report on Monday, December 29th. Canaccord Genuity Group upped their price objective on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a "buy" rating in a report on Monday, December 22nd. Finally, Robert W. Baird raised their price objective on shares of Castle Biosciences from $41.00 to $44.00 and gave the stock an "outperform" rating in a research report on Friday, February 27th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Castle Biosciences presently has an average rating of "Moderate Buy" and an average target price of $47.57.
Get Our Latest Stock Analysis on Castle Biosciences
Castle Biosciences Company Profile
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
